Navigation Links
ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Date:8/19/2007

MISSISSAUGA, ON, Aug. 15 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Oncoscience AG (Wedel, Germany), its European partner for the development of the humanized EGFR-targeting monoclonal antibody, nimotuzumab, has recruited the 40th and final patient in its international phase III trial combining nimotuzumab with radiation for the treatment of children and adolescents suffering from diffuse intrinsic pontine glioma (DIPG). DIPG is an inoperable form of brain cancer for which treatment options are severely limited. The Phase III trial is being conducted by an international group of paediatric oncologists under the lead of principal investigator Professor Udo Bode at the University of Bonn, Germany. The primary end-point of the trial is progression-free survival with overall survival as a secondary endpoint. Nimotuzumab has been designated an Orphan Drug by the EMEA.

"Oncoscience AG is moving to complete this DIPG trial, one in a series that, if successful, will be an important component of our nimotuzumab regulatory strategy," said David Allan, Chairman and CEO of YM BioSciences. "YM has received clearance for a Canadian Phase II trial in children with recurrent DIPG for which the principal investigatory site is the Hospital for Sick Children in Toronto, an internationally recognized Centre of Excellence in paediatric medicine."

Positive European data from a completed second line 47-patient Phase II nimotuzumab monotherapy trial in recurrent pediatric glioma were most recently summarized in an oral presentation at ASCO 2007. The clinical benefi
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. Jellyfish partners for sales tracking technology
6. GE Healthcare partners with UNC on breast cancer imaging research
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Fergus joins Baird Venture Partners, Caden Bio
9. Avolte Venture Partners reaches capital goal
10. NimbleGen partners with UK biotech firm
11. Big pharma seeks Wisconsin biotech partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... DIEGO , July 29, 2015  Pfenex Inc. ... 2015 financial results will be released on Thursday, August ... am Eastern Time, Pfenex management will host a conference ... business update.  A press release outlining the financial results ... the call. Please call 1-866-376-8058 (US) or ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris ... announced it has selected an optimized Erk inhibitor ... in the development of a new class of ... pathway represents a prime target for therapeutic intervention ... activities and survival benefits for B-Raf and Mek ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ ... Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, ... expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... Palo Alto, Calif. - Wisconsin Governor Jim Doyle ... but the subject wasn't the controversial stem cell patent of ... for coalition building on stem cell research, Doyle went after ... limitations on federal funding for human embryonic stem cell research. ...
... - GE Healthcare has fully automated the steps ... cell units at the New York Blood Center's ... the AutoXpress system, developed by ThermoGenesis Corp . and ... the stem cell-rich cord blood into a user-determined final volume ...
... - Before Gov. Jim Doyle began turning up ... research, a key Republican legislator had already turned the tables ... projects, which now are the subject of a state audit, ... by State Sen. Ted Kanavas , R-Brookfield, who has ...
Cached Biology Technology:Doyle, Green exchange stem cell salvos 2Doyle, Green exchange stem cell salvos 3Doyle, Green exchange stem cell salvos 4GE partners with New York blood center 2GOP lawmaker faults Doyle for IT problems 2GOP lawmaker faults Doyle for IT problems 3
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... under Pressure conference is a major international event ... Some 2,500+ leading thinkers in a ... present new findings in climate change, environmental geo-engineering, ... biodiversity, global trade, development, poverty alleviation, food security ...
... padded headgear and gloves reduces the impact that fighters ... published research from Cleveland Clinic. In their ... replicated hook punches to the head using a crash ... under five padding configurations: without headgear or boxing gloves; ...
... is available in German . The fingers ... therefore react faster than the middle finger, which is exposed to ... learning, this speed handicap can be compensated. The working group led ... for Neuroral Computation) report in the current issue of PNAS. ...
Cached Biology News:Planet under pressure 2Planet under pressure 3Padded headgear, boxing gloves may offer some protection for fighters 2Why the middle finger has such a slow connection 2Why the middle finger has such a slow connection 3
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: